Candel Therapeutics (CADL) Research & Development (2020 - 2025)

Candel Therapeutics has disclosed Research & Development across 6 years of filings, most recently posting $6.6 million for Q4 2025.

• Research & Development for Q4 2025 came in at $6.6 million, up 36.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $18.7 million (up 22.43% YoY), and the FY2025 annual result was $14.7 million, down 23.69% from the prior year.
• Research & Development came in at $6.6 million for Q4 2025 at Candel Therapeutics, up from $3.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $7.3 million in Q4 2023 to a low of $921000.0 in Q2 2024.
• The 5-year median for Research & Development is $5.1 million (2021), against an average of $4.7 million.
• Across the five-year window, Research & Development tumbled 84.48% in 2024 and surged 659.07% in 2025, its largest moves.
• Candel Therapeutics' Research & Development stood at $3.9 million in 2021, then grew by 29.01% to $5.0 million in 2022, then surged by 45.98% to $7.3 million in 2023, then slumped by 33.63% to $4.8 million in 2024, then soared by 36.91% to $6.6 million in 2025.
• The last three Research & Development figures came in at $6.6 million (Q4 2025), $3.8 million (Q3 2025), and $7.0 million (Q2 2025), per Business Quant data.